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Background: The recent report of high numbers of Acinetobacter baumannii blood-
stream infections among service members injured in Iraq and Afghanistan during the
periodJanuary 2002throughAugust 2004hasprompted aninvestigationinto theiretiol-
ogy.Ar e view of the current guidelines for open combat casualty wounds as part of this
broad investigation was not mentioned in the report. Objective: The objective of this
study was 2-fold: to ascertain the susceptibility of A baumannii to currently available
topicalantibacterialagentsand(2)toproposeanalternative,effectivetreatmentprotocol
for contaminated combat-related wounds so as to reduce or eliminate the likelihood of
the wound serving as the source of A baumannii infection or septicemia. Methods: A
standardized antimicrobial susceptibility study of 43 strains of A baumannii collected
fromatertiarycareburncenterwasconductedusing2commonlyusedtopicalantibacte-
rial agents, 1% silver sulfadiazine cream (Silvadene) and 5% mafenide acetate solution
(5% Sulfamylon Solution). Results: Both were effective, but 5% Sulfamylon Solution
demonstrated significantly greater antibacterial activity. Conclusion: Five percent Sul-
famylon Solution, initially developed for wartime use, and currently limited by the Food
andDrugAdministrationtosoaksfollowingmeshedsplit-thicknessautograftsfollowing
excision of second-degree and third-degree burns, has a broad spectrum of antibacterial
activity and extensive off-label applicability. It is an ideal agent for use in the treatment
of war wounds, and should be considered as a superior replacement for normal saline in
the current guidelines for open combat casualty wounds
The recent report of an increasing number of Acinetobacter baumannii bloodstream
infections among service members injured in Iraq/Afghanistan operations prompted this
investigation.1 The number of such infections and the resistance of A baumannii infections
to multiple antibiotics suggested the need to consider and address the wounds and their
treatment as a possible cause of septicemia and to suggest an alternative method to de-
crease or eliminate colonized or contaminated wounds as a potential source of A baumannii
sepsis.
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Figure 1. Patient with burns, traumatic amputation left foot and lower leg, and multiple soft tissue
injuries secondary to blast (Afghanistan, 2003).
The present guidelines for care of open combat casualty wounds are as follows:
The standard care for the type of wounds we are seeing from Iraq include vigorous
and complete early irrigation and debridement (Figs 1–3). The wounds are packed with
saline-soaked Kling or ﬁne mesh gauze and left alone for 4 days (Fig 4). The only reason
to take down the dressing and inspect the wound is foul odor, discharge, bleeding, or fever
that cannot be explained without inspecting the wound. At 4 days, the patient is returned
to the operating room for a dressing change. If the wound has that “sticky” appearance
withoutanyareasofnecrosisandneedforfurtherextensivedebridement,aDelayedPrimary
Closure (DPC) is done. If the wound does not appear clean, it is debrided, irrigated, and
packed again (sometimes with Dakin’s solution or whatever solution the surgeon chooses)
and the 4-day clock restarted (judgement call). Those wounds that fail DPC or are so large
that a DPC is not in the plan are treated by wet-to-dry dressing changes. As soon as the
wounds appear clean, Dakin’s solution (or whatever solution is used to clean the wound)
is switched to normal saline.2
Normal saline solution possesses no inherent antibacterial activity, and therefore can-
not be expected to decrease or control bacterial growth in open wounds. Likewise, simple
inspection of such wounds is unreliable in predicting successful DPC.3 Because systemic
antibiotics are ineffective in reducing bacterial counts in granulating wounds, the use of a
topical antibacterial agent that is active in controlling or reducing bacterial proliferation in
open wounds may substantially decrease wound sepsis as a source of morbidity and may
have a beneficial effect on overall management.4,5 Furthermore, the addition of microbi-
ological quantification within the wounds (quantitative bacteriology or swab techniques)
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Figure 2. Debrided shrapnel wounds to right thigh, flank, and abdomen (Afghanistan, 2003).
may provide valuable information regarding efficacy of treatment and the likelihood of
successful DPC.6,7
The efficacy of 5% mafenide acetate solution (5% Sulfamylon Solution [Bertek Phar-
maceutical Inc, Research Triangle Park, NC]) and 1% silver sulfadiazine cream (Silvadene
[Kendall Company, Mansfield, Mass]) was tested against A baumannii derived from burn
isolates at the Shriners’ Burn Institute, Galveston, Tex, in order to determine whether these
topicalantibacterialagents,successfullyemployedinburncare,mightbeeffectiveadjuncts
in controlling A baumannii wound infections in traumatic war wounds.
MATERIALS AND METHODS
All A baumannii isolates from the burn population were routinely tested for their suscepti-
bility to 5% Sulfamylon Solution and Silvadene by a modified Nathan’s agar well assay.
Mueller-Hinton 150 mm agar plates received 6 mm agar wells using a sterile 6 mm
biopsy punch. Once the wells were made, 105 colony-forming units of the organism were
inoculated to each plate. The plates were allowed to dry, and then 0.1 mL of each topical
antimicrobialwasaddedtoeachwellandnumericallyidentified.Atotalof43Acinetobacter
isolates were tested.
The assay plates were incubated at 37◦C for 24 hours. Zones of inhibition were mea-
sured and compared for susceptibility.8
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Figure 3. Surgical team in action (Afghanistan, 2003).
RESULTS
Table1gives the average zones of inhibition for Silvadene and Sulfamylon against A
baumannii. Sulfamylon treatment had a significantly greater zone of inhibition than did
Silvadene treatment (P = .05).
Statistical assessment
Zones of inhibition for the 2 topical antimicrobials were compared using a 1-way analysis
of variance followed by a Tukey’s test. Statistical significance was set at P < .05.
DISCUSSION
The emergence of an increased number of bloodstream infections due to antibiotic-
resistant Abaumannii among service members wounded during Operation Enduring Free-
dom (Afghanistan) and Operation Iraqi Freedom (Iraq/Kuwait) from the period January
2002throughAugust2004hasfocusedattentionontheissuesofinfectioncontrolincombat
settings and healthcare facilities (field hospitals, combat theater medical facilities, military
medical centers) and the need for new, effective antibiotics to treat these infections. Us-
ing the criteria established by the Centers for Disease Control and Prevention’s National
Nosocomial Infection Surveillance system, data compiled during this period identified 102
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Figure 4. Normal saline–soaked dressing being applied to open abdominal wound (Afghanistan,
2003).
patients with blood cultures positive for A baumannii. Of the 102 service members, 85
(83%) sustained wounds during either military operation.1
A baumannii is ubiquitous and has recently become one of the most important
healthcare-associated hospital pathogen, resulting in significant morbidity and mortality.
Overthelast40years,nosocomialinfectionscausedbythisagenthavebecomeincreasingly
problematic, posing significant therapeutic challenges due to multiple antibiotic resistance,
persistent colonization, and prolonged environmental survivability. A baumannii has been
the cause of infections in patients suffering from traumatic injuries and was the most com-
mon gram-negative bacillus isolated from traumatic extremity injuries during the Vietnam
War.9–14 Therefore, environmental contamination of wounds with A baumannii must be
considered as a possible source of infection. Presently, it is not known when or where
Table 1. Average ± standard error of inhibition for Silvadene
and Sulfamylon against Acinetobacter baumannii
Average ± standard error
of inhibition, mm
Organism Total number Silvadene Sulfamylon Value
A baumannii 43 15 ± 12 3 ± 1 P < .05
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military personnel who served in Operation Enduring Freedom or Operation Iraqi Freedom
acquired the infections: in the field, during evacuation, or during treatment.
Theinformationcompiledonthesepatientsiscurrentlyunderreview.Multiplefactors,
includingantimicrobialexposure,mechanicalventilation,vascularaccess,andevacuationof
patientsthroughtreatmentfacilities,areimplicated.Microbiologicalandmolecularanalyses
of patient and environmental isolates are being conducted to determine the likely sources of
infection.However,neitherthecurrentstandardguidelinesforcareofopencombatcasualty
wounds have been reviewed nor has any consideration been given to assess more effective
ways to ensure bacteriologic control of the wounds to reduce the possibility of the wound
serving as the septic source.1
The present guidelines for the care of open combat casualty wounds require vigorous
irrigation, debridement, saline-soaked dressings, and reinspection at 96 hours, unless oth-
erwise required. DPC is performed on wounds with that sticky appearance. Wounds not
amenable to DPC undergo additional wound care and dressing changes employing wet-to-
dry dressings, Dakin’s solution or “whatever solution the surgeon chooses,” and normal
saline.2
Thepurposeofthisstudywas2-fold:(1)toascertainthesusceptibilityofAbaumannii
to currently available topical antibacterial agents and (2) to propose an alternative, effective
treatment protocol for contaminated combat-related wounds so as to reduce or eliminate
the likelihood of the wound serving as the source of A baumannii infection or septicemia.
This study showed the efficacy of 2 commonly used topical antibacterial agents, 1%
silver sulfadiazine cream (Silvadene) and 5% mafenide acetate solution (5% Sulfamylon
Solution), against a large number of strains of A baumannii. The latter demonstrated sig-
nificantly greater activity against A baumannii than did 1% silver sulfadiazine cream.
Topicalantibacterialagentsareroutinelyemployedinburncaretopreventburnwound
sepsis, but their use in nonburn wounds has been generally limited and underappreciated.
Nevertheless,theseagents,and5%mafenideacetatesolutioninparticular,havebeeneffec-
tivelyutilizedinthemanagementofnonburnwoundsandshouldbeconsideredasimportant
adjuncts in the management of acute and chronic open wounds. The product indications
for 5% Sulfamylon Solution have been severely limited by the Food and Drug Administra-
tion to use over meshed split-thickness skin grafts following excision of second-degree and
third-degree burn wounds. However, the overall utility of this agent in off-label indications,
including contaminated and infected wounds, has been clearly demonstrated since World
WarI Iand is unsurpassed. 15–17
The demonstration in this study of the antibacterial efficacy of 5% mafenide acetate
solution against A baumannii is neither an accident nor serendipity. Mafenide, either as
hydrochloride or as acetate, has been shown to be an effective topical antibacterial agent
sinceitsadoptionbytheGermanArmyinWorldWarII.NumerousstudiesconductedbyDr
Janice Mendelson and by Drs John Moncrief and Robert Lindberg at the US Army Institute
of Surgical Research, Brooke Army Medical Center, Fort Sam Houston, Tex, confirmed its
effectiveness in the research laboratory and in the clinical setting. 17–21
Fivepercentmafenideacetatesolution(5%SulfamylonSolution)isespeciallyeffective
in the treatment of burns, blast injuries, open fractures, synergistic gangrene, and necrotiz-
ingfasciitis.Itretainsitsactivityinthepresenceofbloodandpus,andcanpenetratebeneath
thesurfaceofthewoundtoexertitsantibacterialeffectsonbothviableandnonviabletissue.
It is not cytotoxic, may stimulate angiogenesis, and exerts its activity directly at the wound
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site. It is highly effective against both gram-positive and gram-negative bacteria, including
anaerobes. It has no antifungal activity. Studies of the agent conducted against numer-
ous strains of gram-positive and gram-negative organisms, including methicillin-resistant
Staphylococcusaureus,v ancomycin-resistantenterococcus,Pseudomonasaeruginosa,and
Acinetobacer species, isolated from a broad array of clinical situations showed complete
activity. In another study of more than 11,000 strains of P aeruginosa, collected over 25
years at the US Army Institute of Surgical Research, Brooke Army Medical Center, Fort
Sam Houston, Tex, there was no evidence of resistance to 5% Sulfamylon Solution. 15–28
Mafenide acetate powder is stable and autoclavable and requires no refrigeration. It
is supplied in drums and is then dispensed in 50 g premeasured packets of powder. Fifty
grams of powder is mixed with1Lo fsterile water to yield a 5% solution of the agent. The
resultant solution is clear and colorless and can be applied to wounds in the same fashion
as is normal saline. Rather then relying on a single application of normal saline, which
has no antibacterial activity and may predispose the wound to bacterial proliferation, 5%
Sulfamylon Solution exerts a powerful, continuous antibacterial effect on a broad range of
bacteria, including A baumannii. The dressings need to be remoistened with Sulfamylon
Solution at regular intervals (6–8 hours) to prevent wound dessication and to maintain
antibacterial potency.15,27
This agent was developed for wartime requirements and is the ideal topical agent
for wound care in difficult environments. It is highly effective against the pathogens most
commonly encountered in massive traumatic injuries, blasts, gunshot wounds, burns, and
open fractures. Because of its aqueous nature it can be easily incorporated into dressings
as a soak and it permits easy inspection of the wound. It can be applied with spray bottles
or injected into rubber catheters that have been incorporated into the dressings in order to
maintain antibacterial control.
The inclusion of bacteriological monitoring of the wound (quantitative bacteriology or
swab techniques) into the overall wound management protocol may be helpful in gauging
the efficacy of wound treatment and the suitability of the wound for DPC.3,7
CONCLUSION
The increased incidence of A baumannii septicemia involving service members wounded
duringOperationIraqiFreedomandOperationEnduringFreedomhaspromptedathorough
investigationtodeterminethesourceoftheinfectionsandtodecreasetheirlikelihoodinthe
future.Theinvestigationisfocusingonmanyvariablesandfactorsthatmayplayacausative
role. Current treatment guidelines for open combat casualty wounds were not mentioned as
part of the review.
The standard protocol currently in use relies on the fundamental concepts of adequate
debridement and copious wound irrigation but does not provide for ongoing antibacterial
activity within the wound prior to DPC.
Five percent Sulfamylon Solution was tested against numerous A baumannii isolates
and exerted a strong antibacterial effect as demonstrated by large zones of inhibition in a
standardized microbial susceptibility assay. The historical and current clinical and labora-
tory data clearly support the efficacy and utility of this topical agent in a wide variety of
soft tissue wounds and infections. This agent was initially developed for wartime use and
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should be considered as part of the battlefield casualty antibacterial armamentarium. By
substituting this agent for normal saline in the treatment protocol of open combat casualty
wounds, reliable and effective bacteriologic control of the wound from the entire spectrum
of battlefield bacterial contaminants (gram-positive and gram-negative) can be achieved.
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